tbuckley/cabot-search huggingface dataset:
OP0129 Mycophenolate mofetil versus cyclophosphamide in scleroderma-related interstitial lung disease in a real life scenario
Authors: H Fretheim, Ø Midtvedt, E Volkmann, T Garen, MB Lund, T Aaløkken, Ø Molberg, A-M Hoffmann-Vold
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic sclerosis (SSc) is a serious disease with high risk of interstitial lung disease (ILD); a feared complication with poor prognosis. The SLS 2<sup>1</sup> supported the clinical effectiveness of Mycophenolate Mofetil (MMF) and Cyclophosphamide (Cyc). <h3>Objectives</h3> Evaluate the effect of MMF and Cyc on SSc-ILD in a population based cohort. <h3>Methods</h3> All SSc patients at Oslo University Hospital (OUH) are included in an prospective, observational SSc cohort. All patients are followed annually by rheumatologists and data are recorded in the Norwegian systemic connective tissue disease registry (NOSVAR). Here, we assessed patients diagnosed after the year 2000 (n=433). Longitudinal pulmonary function tests (PFTs), HRCT lung image results, pulmonary hypertension (PH), clinical and demographic data, antibodies and vital status were obtained from NOSVAR. Outcome measures were vital status in December 2016, extent of fibrosis measured on HRCT, FVC and DLCO development. <h3>Results</h3> Among 262 patients with complete data on treatment and ILD, 21 (8%) patients received treatment with Cyc, 14 (5.3%) with MMF and 17 (6.5%) with combination therapy of MMF and Cyc. 55.7% of patients did not receive any treatment for ILD. Baseline characteristics, lung fibrosis and function did not differ significantly between the MMF and Cyc (Table 1). Patients treated with Cyc show a trend of higher mortality. Treatment with Cyc resulted in a significant improvement of lung fibrosis; whereas treatment with MMF resulted in significant progression in lung fibrosis (-1.3% (SD 9.3) and 7.5% (SD 11.1), p=0.024) (Table 1). MMF treatment showed a significant improvement in the DLCO% (1.8% [SD 4.6]); whereas Cyc had a significant decline in the DLCO% (-2.1% [SD 3.5], p=0.14). Less patients treated with MMF developed PH compared with Cyc treatment (1[7.7%] compared to 8[42.1%], p=0.038) (Table 1). <h3>Conclusions</h3> Preliminary data from our population based cohort indicate that in a real-life scenario treatment effects of Cyc and MMF appear comparable to randomized clinical trials, but there are some potentially important nuances. Cyc seems to halt fibrosis progression, but toxicity is a major concern, while MMF could have effects on DLCO decline and the development of PH. <h3>References</h3> Tashkin DP et al. Mycophenolate mofetil versus oral cyclophosphamide in SLS II. Lancet Respir Med. 2016. <h3>Disclosure of Interest</h3> None declared
知能:78,308人のゲノムワイド関連メタ解析による,ヒトの知能に影響を及ぼす新規座位および遺伝子の同定
Authors: Sniekers Suzanne, Stringer Sven, Watanabe Kyoko, Jansen Philip R, Taskesen Erdogan, Hammerschlag Anke R, Okbay Aysu, Koellinger Philipp, Posthuma Danielle, Tiemeier Henning, Coleman Jonathan R I, Krapohl Eva, Zabaneh Delilah, Breen Gerome, Plomin Robert, Rietveld Cornelius A, Amin Najaf, Van Duijn Cornelia M, Cesarini David, Chabris Christopher F, Iacono William G, Lee James J, Mcgue Matt, Miller Mike B, Ikram M Arfan, Johannesson Magnus, Magnusson Patrik K E, Ollier William E R, Payton Antony, Pendleton Neil
Journal: Nature Genetics (2017)
FRI0755-HPR Potential benefits of biologics on cardiovascular diseases and orthopedic surgeries in patients with rheumatoid arthritis: a nationwide population-based cohort study in taiwan
Authors: D-Y Chen, C-H Tang, F Yu, C-Y Huang
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder, precipitating chronic inflammation of the joints, and also affects organs throughout the body, and even results in joint deterioration/disability. RA-related inflammation that is responsible for synovial lesions may be implicated in the development of accelerated atherosclerosis, leading to increased risk of cardiovascular disease (CVD), and increased mortality. <h3>Objectives</h3> This study aimed at examining changes in the risk of deaths, CVD and RA-related orthopedic surgeries between the patients treated with conventional synthetic and biologic disease modifying antirheumatic drugs (csDMARD and bDMARD) for RA during 1997–2011. <h3>Methods</h3> Two cohorts of severe RA patients and their matched controls were identified from National Health Insurance claims database. The csDMARD cohort was patients who had medication claim for cyclosporine ≥50 mg/day with concomitant use of ≥2 csDMARDs for ≥28 days within 56 days after cyclosporine use during 1997–2003 (N=1,569). After csDMARD cohort was determined, the bDMARD cohort was selected if patients had ≥1 claim for bDMARD during 2003–2011 (N=1,530). Adjusted hazard ratios (aHRs) for the risk of death, myocardial infarction (MI), stroke, and RA-related orthopedic surgeries were assessed between the two cohorts and their controls, respectively, using Kaplan-Meier survival curves and Cox proportional hazards models. <h3>Results</h3> RA patients using bDMARD showed a markedly decreased risk of death (aHR:1.05; 95% CIs=0.84–1.33) compared with RA patients using csDMARD (aHR:8.75; CIs=7.43–10.31). Also, bDMARD was associated with a reduced risk of stroke (aHR:0.37; CIs=0.22–0.62) compared with csDMARD (aHR:0.73; CIs=0.51–1.05). For RA-related orthopedic surgeries, risks were slightly lower for bDMARD (aHR:4.14; CIs=3.30–5.20) compared with csMARD (aHR:5.77;CIs=4.88–6.81). <h3>Conclusions</h3> The introduction of biologics in the treatment of RA has showed to have beneficial impact on improving clinical outcomes, including decreased risks of death, stroke and RA-related orthopedic surgeries. <h3>References</h3> Avina-Zubieta JA, et al. Ann Rheum Dis. 2012 Sep;71(9):1524–1529. Maradit-Kremers H, et al. Arthritis Rheum. 2005 Feb;52(2):402–411. <h3>Acknowledgements</h3> NA. <h3>Disclosure of Interest</h3> D.-Y. Chen: None declared, C.-H. Tang: None declared, F. Yu Employee of: Pfizer Ltd., C.-Y. Huang: None declared
SAT0420 Relationship between health-related quality of life with disease activity and functional status, in patients with ankylosing spondylitis
Authors: P Chiowchanwisawakit, V Srinonprasert, W Katchamart
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic disease resulting in diminished quality of life (QoL). There was no study regarding QoL in Thai patients with AS. <h3>Objectives</h3> To identify factors associated with quality of life, measured by EuroQol 5-dimension, 5-level questionnaire (EQ-5D-5L), in patients with AS. <h3>Methods</h3> This was a cross-sectional study. Demographic data and outcomes related to health utility or HU [Thai version EQ-5D-5L], disease activity [BASDAI (0–10), ASDAS-ESR or CRP, number of tender (TJC) and swollen joint (SJC), and enthesitis], and functional status [BASFI (0–10) and HAQ (0–3)] were collected. The HU was calculated on the basis of responses to 5-domains using the Thai value set. Regression analysis was used to explore factors associated with each EQ-5D domain and HU. Multiple models using different outcome measures for disease activity and functional status were performed to identify the best predictive model. <h3>Results</h3> Among 119 AS patients, most (73%) were male with mean (SD) age of 40.4 (11.6) years. Most (52.9%) were married and 92 (77.3%) were employed. The median (IQR) disease duration, BASDAI, BASFI, and HAQ were 7.5 (11.8) years, 3.2 (3.7), 2.3 (4.2), and 0.4 (0.9), respectively. The mean (SD, range) EQ-5D and VAS were 0.75 (0.20, -0.24–1.00) and 68.8 (18.8, 10–100), respectively. In univariate analysis, higher disease activity, higher functional index score, and more severe peripheral joint involvement were significantly associated with lower HU and moderate to very severe problem in each EQ-5D domain compared with no to mild problem with p&lt;0.05, except SJC which was not associated with mobility problem. Conversely, age, gender, marital status, and disease duration were not associated with any EQ-5D domains or HU. In multivariate regression analysis, disease activity and functional status were significantly associated with HU (Table 1), when adjusted for age. The best predictive model using BASDAI, CRP, and HAQ with adjusted for age correctly predicted 77.4% of the variance in HU, while using BASFI instead of HAQ in the same model yielded slightly lower predictive value of 70.7%. <h3>Conclusions</h3> Disease activity and functional status were significantly factors related to QoL and HU in patients with AS. To improve QoL, the aim of treatment should be achieve remission or at least low disease activity and improve or at least maintain function. <h3>Disclosure of Interest</h3> P. Chiowchanwisawakit Grant/research support from: Siriraj Research fund, V. Srinonprasert: None declared, W. Katchamart: None declared
Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?
Authors: Massimiliano Mazzone, Veronica Finisguerra, Hans Prenen
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Robust Production of Cytomegalovirus pp65-Specific T Cells By a Fully Automated IFN-γ Cytokine Capture System
Authors: Nayoun Kim, Young-Sun Nam, Keon-Il Im, Jung-Yeon Lim, Young-Woo Jeon, YuneJin Song, Jong Wook Lee, Seok-Goo Cho
Journal: Blood (2016)
Annals Story Slam - Good and Bad Times
Authors: Thomas Bodley
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 September 2017Annals Story Slam - Good and Bad TimesFREEThomas Bodley, MDThomas Bodley, MDFrom University of Toronto, Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0062 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Good and Bad Times "Good and Bad Times," by Dr. Thomas Bodley (Duration 05:44)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Toronto, Toronto, Ontario, Canada.Current Author Address: Thomas Bodley, MD, University of Toronto, Toronto, Ontario, Canada; e-mail, Thomas.[email protected]utoronto.ca. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: SS1 ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Humanitarian Surgical Care in the US Military Treatment Facilities in Afghanistan From 2002 to 2013
Authors: Sharon R. Weeks, John S. Oh, Eric A. Elster, Peter A. Learn
Journal: JAMA Surgery (2017)

This study uses the database Patient Administration Systems and Biostatistics Activity to examine the breadth of war-related and non–war-related surgical procedures provided by deployed military surgeons to locals in Afghanistan from 2002 to 2013.
It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics
Authors: Vasily Shuvaev, Mikhail Fominykh, Vera Udaleva, Irina I Zotova, Regina Golovchenko, Dzhariyat Shikhbabaeva, Irina Martynkevich, Lyudmila Martynenko, Marina Ivanova, Natalya Tsybakova, Ekaterina Motyko, Lyubov Polushkina, Nadezhda Potikhonova, Sophya Tyranova, Marina Zenina, Kudrat Abdulkadyrov
Journal: Blood (2016)
AB1078 Impact of pre-screening on rheumatology outpatient clinic practice
Authors: C Orr, O McElvaney, M McQuillan, M Hussein, S Donnelly, G McCarthy, C McCarthy
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Chronic rheumatological diseases are predominantly managed in an outpatient setting, and these out patient clinics constitute a significant workload for rheumatolgy clinicicians. When unnecessary outpatient visits occur, service provision to those most in need of rheumatology review, both new referrals and those with established diagnoses in need of urgent review, is compromised. There is an evidence base for such screening in secondary care centres from other internal medicine disciplines (1). <h3>Objectives</h3> To determine the impact of introducing pre-clinic screening, and exploring the potential for follow up using telephone, by a physician extender (PE), on attendances at a rheumatology outpatient department. <h3>Methods</h3> A retrospective chart review of all patients attending a rheumatology outpatient clinic was performed over a 4-week period, 15/08/2016- 09/09/2016. Patients were categorized into new or follow-up attendees and the follow-up patients were further subcategorized into 1 of 4 groups: A) Attending to receive results of investigations requiring no further treatment; B) Attending with a chronic rheumatological disease requiring no active change in management; C) Attending to receive results of investigations requiring further treatment; D) Attending with a chronic rheumatological disease requiring active change in management. Patients in categories A and B, may be safely managed by a phone call from a physician, or PE. Those in C and D would need to be reviewed in clinic, following triage by phone using a PE. <h3>Results</h3> 232 subjects were included (5 category A, 118 category B, 4 category C, 105 category D). 123 (53.0%) could be managed by phone utilizing a PE, thus obviating the need for review in clinic. The remaining patients could be triaged by telephone by a PE, and the schedule for review adjusted to prioritise those most in need of review. It is likely that such a strategy for reviewing patients would be more clinically efficient, have a greater impact on patient well-being, and be cost-saving. <h3>Conclusions</h3> Routine pre-screening for patients attending rheumatology clinics should be considered to improve effectiveness of the commodity rheumatology expertise. <h3>References</h3> Donnellan, F., Harewood, G.C., Cagney, D., Basri, F., Patchett, S.E. and Murray, F.E., 2010. Economic impact of prescreening on gastroenterology outpatient clinic practice. Journal of clinical gastroenterology, 44(4), pp.e76-e79. <h3>Disclosure of Interest</h3> None declared
AB1199-HPR Improving triage to appropriate treatment level by using a combination of screening tools in patients at risk of developing chronic back pain
Authors: E Haglund, C Olsson, A Bremander, S Bergman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The screening instrument STarT (Subgroups for Targeted Treatment) Back Screening Tool (SBST) identify patients at risk of developing chronic back pain in order to facilitate triage to appropriate treatment level. The SBST takes into account known risk factors such as activity limitations, kinesiophobia and psychological health. However, SBST does not consider pain distribution which is a known predictor of chronic widespread pain (CWP). According to evidenced clinical practice patients with CWP should be referred to multimodal rehabilitation (1). <h3>Objectives</h3> The purpose of the study was to compare screening by SBST with screening of multisite chronic widespread pain (MS-CWP) in a group of patients with back pain and to analyze to what extent the two screening methods identify the same patients at higher risk. <h3>Methods</h3> 73 individuals with a report of chronic back pain (≥3 months during last year) age 40–70 years responded to both screening tools. The SBST stratify patients into low, medium or high risk groups. A pain mannequin was used to categorize patients into no chronic pain (NCP), chronic regional pain (CRP) or chronic widespread pain (CWP) and number of painful areas (0–18). A presence of a CWP in combination with ≥7 painful areas was stratified as MS-CWP. The outcome of the different screening tools was analyzed by cross tabulations. The Roland-Morris Disability Questionnaire (RMDQ, 0–24), health related quality of life (EQ5D, 0–1), Fear-Avoidance Beliefs Questionnaire about physical activity (FABQ-PA, 0–24) and work (FABQ-Work, 0–42), Hospital Anxiety (HAD-A, 0–21) and Depression scale (HAD-D, 0–21) were used to describe physical function, health related quality of life, kinesiophobia and mental health. <h3>Results</h3> The mean (SD) age was 59 (8) years, 63% were women. Self-reports of physical function (RMDQ) were 4.5 (4.8), health related quality of life (EQ5D) 0.71 (0.21), kinesiophobia (FABQ-PA and FABQ-Work) 8.3 (5.9) and 14.7 (11.1), and mental health (HAD-A and HAD-B) 8.8 (2.0) and 4.5 (1.7). Comparing the different screening methods, 5 patients (7%) were at high risk as captured by SBST while using the pain mannequin 38 (52%) patients had CWP and 22 (30%) had MS-CWP. No patients in the SBST high risk group had NCP, but 31 (50%) in the SBST low risk group reported CWP, and 16 (26%) reported MS-CWP. In the medium risk group 3 reported CWP, and 3 were also categorized as MS-CWP. <h3>Conclusions</h3> SBST and the pain mannequin as screening tools partly capture different patients at high risk of developing chronic back pain. Using a combination of the two instruments may improve the ability to facilitate triage to appropriate treatment level. <h3>References</h3> Macfarlane GJ et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–328. <h3>Disclosure of Interest</h3> None declared
AB0921 Infectious spondylodiscitis: epidemiological, clinical, paraclinical and therapeutic aspects
Authors: A Feki, R Akrout, I Sellami, M Ezzeddine, H Fourati, S Baklouti
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Spondylodiscitis is an infection of a disc and the two adjacent vertebrae due to the introduction of a pyogenic, usually by the haematogenous route. It9s quite a rare disease accounting for 2–7% of all cases of septic osteomyelitis [1, 2]. <h3>Objectives</h3> To study the clinical, microbiological, radiological, therapeutic and evolving of infectious spondylodiscitis <h3>Methods</h3> A retrospective descriptive study conducted over years in the department of rheumatology, including all patients with infectious spondylodiscitis. Clinical given were collected from paper patients records. <h3>Results</h3> We included 67 patients. There were 38 men and 29women. The mean age was 55 years. The male to female ratio was 38:29.Risk factors of spondylodiscitis were observed in 19 patients. The approximate time from onset of symptoms to diagnosis was from 3 to 365 days (median, 132 days). Back pain was the most common symptom. Spinal syndrome was found in all patients. The most frequent location of spondylodiscitis was lumbar spine. Signs of spinal cord compression including paraplegia or paraparesis of the lower limbs were observed in 31 patients. Pachymeningitis was associated in 1 case. The paravertebral abscess was associated to the disc involvement in 23 cases. Epiduritis was associated in 21 cases. Plain radiography, performed in in the majority of cases (63 cases, 94%), demonstrated pathological pictures in 56 (83.5%) patients. MRI, performed in 60 (89.5%) patients, disease was in all patients. Pathogens were isolated in 43 (64.1%) cases. Tuberculosis was the most common cause. The leading causative agents in non tuberculousspondylodiscitis were: Staphylococcus aureus (8 isolates, 11.9%), brucella (7 isolates, 10.4%), Escherichia coli (2 isolates, 2.9%) and streptococcus B (1 isolates, 1.4%).Two microorganisms combined (mycobacterium tuberculosis and a pyogenic) was found in one case. Medical treatment was adapted to the prescribed seed. Surgical treatment was performed in 6 patients. After therapy, 59 (88%) patients had regression of symptoms, two patients had a permanent neurological impairment (paraplegia), one patient had recurrence of infection and one patient was dead. <h3>Conclusions</h3> Infectious spondylodiscitis has been diagnosed with increasing frequency. It should be taken into consideration in differential diagnosis in patients with significant back pain and laboratory evidence of an acute inflammatory process, especially metastatic spinal disease or inflammatory spondyloarthritis <h3>References</h3> Zimmerli W. Clinical practice.Vertebralosteomyelitis. N Engl J Med 2010 Mar;362(11):1022–9. Cottle L, Riordan T. Infectious spondylodiscitis. J Infect 2008 June;56(6):401–12. <h3>Disclosure of Interest</h3> None declared